DURECT Corporation to Announce Third Quarter 2024 Financial Results and Provide a Business Update
DURECT (Nasdaq: DRRX), a late-stage biopharmaceutical company focused on epigenetic therapies, announced it will release its third quarter 2024 financial results on Wednesday, November 13, 2024. The company will host a conference call and webcast with investors at 4:30 pm Eastern Time to discuss financial results and provide a corporate update. Participants can join via toll-free number (1-877-407-0784), international number (1-201-689-8560), or through the Call Me™ link and webcast platform.
DURECT (Nasdaq: DRRX), un'azienda biofarmaceutica in fase avanzata focalizzata su terapie epigenetiche, ha annunciato che rilascerà i suoi risultati finanziari del terzo trimestre 2024 mercoledì 13 novembre 2024. L'azienda terrà una teleconferenza e una web conferenza con gli investitori alle 16:30 ora orientale per discutere i risultati finanziari e fornire un aggiornamento aziendale. I partecipanti possono unirsi tramite numero verde (1-877-407-0784), numero internazionale (1-201-689-8560) o tramite il link Call Me™ e la piattaforma web.
DURECT (Nasdaq: DRRX), una compañía biofarmacéutica en etapa avanzada enfocada en terapias epigenéticas, anunció que publicará sus resultados financieros del tercer trimestre de 2024 el miércoles 13 de noviembre de 2024. La compañía llevará a cabo una conferencia telefónica y una transmisión web con los inversores a las 4:30 p.m. hora del Este para discutir los resultados financieros y proporcionar una actualización corporativa. Los participantes pueden unirse a través de un número gratuito (1-877-407-0784), número internacional (1-201-689-8560), o a través del enlace Call Me™ y la plataforma de transmisión web.
DURECT (Nasdaq: DRRX)는 에피제네틱 치료에 중점을 둔 후기 단계의 생명공학 회사로, 2024년 3분기 재무 실적을 2024년 11월 13일 수요일에 발표한다고 발표했습니다. 회사는 동부 표준시 기준 오후 4:30에 투자자들과 함께 재무 결과를 논의하고 기업 업데이트를 제공하기 위해 전화 회의 및 웹캐스트를 개최할 예정입니다. 참가자는 무료 전화번호 (1-877-407-0784), 국제 전화번호 (1-201-689-8560) 또는 Call Me™ 링크와 웹캐스트 플랫폼을 통해 참여할 수 있습니다.
DURECT (Nasdaq: DRRX), une entreprise biopharmaceutique en phase avancée spécialisée dans les thérapies épigénétiques, a annoncé qu'elle publiera ses résultats financiers du troisième trimestre 2024 le mercredi 13 novembre 2024. L'entreprise organisera une conférence téléphonique et un webinaire avec les investisseurs à 16h30, heure de l'Est, pour discuter des résultats financiers et fournir une mise à jour sur l'entreprise. Les participants peuvent rejoindre via le numéro gratuit (1-877-407-0784), le numéro international (1-201-689-8560), ou via le lien Call Me™ et la plateforme de webinaire.
DURECT (Nasdaq: DRRX), ein biopharmazeutisches Unternehmen in der späten Entwicklungsphase, das sich auf epigenetische Therapien konzentriert, hat angekündigt, dass es seine Finanzergebnisse für das dritte Quartal 2024 am Mittwoch, den 13. November 2024, veröffentlichen wird. Das Unternehmen wird um 16:30 Uhr Eastern Time eine Telefonkonferenz und einen Webcast mit Investoren abhalten, um die Finanzergebnisse zu besprechen und ein Unternehmensupdate zu geben. Teilnehmer können über die gebührenfreie Telefonnummer (1-877-407-0784), die internationale Nummer (1-201-689-8560) oder über den Call Me™-Link und die Webcast-Plattform teilnehmen.
- None.
- None.
Wednesday, November 13th @ 4:30 pm Eastern Time / 1:30 pm Pacific Time
Toll Free: | 1-877-407-0784 | |
International: | 1-201-689-8560 | |
Call Me: | https://callme.viavid.com/viavid/?callme=true&passcode=13740526&h=true&info=company |
Participants can use guest dial-in numbers above to reach an operator or they can click the Call meTM link for instant telephone access to the event (dial-out). The Call me™ link will be made active 15 minutes prior to the scheduled start time.
About DURECT Corporation
DURECT is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury. Larsucosterol, DURECT's lead drug candidate, binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in AH patients. Larsucosterol is in clinical development for the potential treatment of AH, for which the FDA has granted a Fast Track and a Breakthrough Therapy designation; MASH is also being explored. In addition, POSIMIR®(bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the innovative SABER®platform technology, is FDA-approved and is exclusively licensed to Innocoll Pharmaceuticals for sale and distribution in the
DURECT Forward-Looking Statements
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, relating to: our plans to report third quarter financial results on November 13, 2024 and the potential for larsucosterol to treat AH. Actual results may differ materially from those contained in the forward-looking statements contained in this press release, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties that could cause actual results to differ from those projected include, among other things, the risk that we do not raise sufficient capital to commence or complete the Phase 3 trial of larsucosterol in patients with AH or continue to fund our operations, the risk that future clinical trials of larsucosterol are delayed or do not confirm the results from subset analyses of the AHFIRM trial, including geographic or other segmentation, or of earlier clinical or pre-clinical trials, or do not demonstrate the safety or efficacy of larsucosterol in a statistically significant manner; the risk that the FDA or other government agencies may require additional clinical trials for larsucosterol before approving larsucosterol for the treatment of AH, the risk that Breakthrough Therapy designation does not expedite the process for FDA approval and that larsucosterol may never be approved; and risks related to the sufficiency of our cash resources, our anticipated capital requirements, our our ability to continue to meet the minimum bid price for continued listing on Nasdaq, and our ability to continue to operate as a going concern. Further information regarding these and other risks is included in DURECT's most recent Securities and Exchange Commission (SEC) filings, including its annual report on Form 10-K for the year ended December 31, 2023, and quarterly report on Form 10-Q for the quarter ended September 30, 2024, when filed, under the heading "Risk Factors." These reports are available on our website www.durect.com under the "Investors" tab and on the SEC's website at www.sec.gov. All information provided in this press release and in the attachments is based on information available to DURECT as of the date hereof, and DURECT assumes no obligation to update this information as a result of future events or developments, except as required by law.
NOTE: POSIMIR® is a trademark of Innocoll Pharmaceuticals, Ltd. in the
View original content to download multimedia:https://www.prnewswire.com/news-releases/durect-corporation-to-announce-third-quarter-2024-financial-results-and-provide-a-business-update-302298018.html
SOURCE DURECT Corporation
FAQ
When will DURECT (DRRX) report Q3 2024 earnings?
How can investors join DURECT 's (DRRX) Q3 2024 earnings call?